BNT162b2 COVID-19 vaccination in children alters cytokine responses to heterologous pathogens and Toll-like receptor agonists

Frontiers in Immunology

Immunology

Susie Germano¹  Emma Burrell¹  Thanh D. Dang¹  Christine Axelrad¹  Nicole L. Messina²  Andrés Noé³  David Burgner⁴  Nigel Curtis⁴  Sonja Elia⁵  Kirsten P. Perrett⁶ 

[1] Infection, Immunity and Global Health, Murdoch Children’s Research Institute, Parkville, VIC, Australia;Infection, Immunity and Global Health, Murdoch Children’s Research Institute, Parkville, VIC, Australia;Department of Paediatrics, The University of Melbourne, Parkville, VIC, Australia;Infection, Immunity and Global Health, Murdoch Children’s Research Institute, Parkville, VIC, Australia;Infectious Diseases Unit, The Royal Children’s Hospital, Melbourne, Parkville, VIC, Australia;Infection, Immunity and Global Health, Murdoch Children’s Research Institute, Parkville, VIC, Australia;Infectious Diseases Unit, The Royal Children’s Hospital, Melbourne, Parkville, VIC, Australia;Department of Paediatrics, The University of Melbourne, Parkville, VIC, Australia;Infectious Diseases Unit, The Royal Children’s Hospital, Melbourne, Parkville, VIC, Australia;Infectious Diseases Unit, The Royal Children’s Hospital, Melbourne, Parkville, VIC, Australia;Department of Paediatrics, The University of Melbourne, Parkville, VIC, Australia;Population Health, Murdoch Children’s Research Institute, Parkville, VIC, Australia;

关键词: SARS-CoV-2;    heterologous;    immunisation;    paediatric vaccination;    innate immunity;    off-target effects;    BNT162b2;    mRNA vaccination;   

DOI  :  10.3389/fimmu.2023.1242380

 received in 2023-06-19, accepted in 2023-07-24,  发布年份 2023

来源: Frontiers

【 摘 要 】

BackgroundVaccines can have beneficial off-target (heterologous) effects that alter immune responses to, and protect against, unrelated infections. The heterologous effects of COVID-19 vaccines have not been investigated in children.AimTo investigate heterologous and specific immunological effects of BNT162b2 COVID-19 vaccination in children.MethodsA whole blood stimulation assay was used to investigate in vitro cytokine responses to heterologous stimulants (killed pathogens, Toll-like receptor ligands) and SARS-CoV-2 antigens. Samples from 29 children, aged 5-11 years, before and 28 days after a second BNT162b2 vaccination were analysed (V2 + 28). Samples from eight children were analysed six months after BNT162b2 vaccination.ResultsAt V2 + 28, interferon-γ and monocyte chemoattractant protein-1 responses to S. aureus, E. coli, L. monocytogenes, BCG vaccine, H. influenzae, hepatitis B antigen, poly(I:C) and R848 stimulations were decreased compared to pre-vaccination. For most of these heterologous stimulants, IL-6, IL-15 and IL-17 responses were also decreased. There were sustained decreases in cytokine responses to viral, but not bacterial, stimulants six months after BNT162b2 vaccination. Cytokine responses to irradiated SARS-CoV-2, and spike glycoprotein subunits (S1 and S2) were increased at V2 + 28 for most cytokines and remained higher than pre-vaccination responses 6 months after BNT162b2 vaccination for irradiated SARS-CoV-2 and S1. There was no correlation between BNT162b2 vaccination-induced anti-SARS-CoV2-receptor binding domain IgG antibody titre at V2 + 28 and cytokine responses.ConclusionsBNT162b2 vaccination in children alters cytokine responses to heterologous stimulants, particularly one month after vaccination. This study is the first to report the immunological heterologous effects of COVID-19 vaccination in children.

【 授权许可】

Unknown   
Copyright © 2023 Noé, Dang, Axelrad, Burrell, Germano, Elia, Burgner, Perrett, Curtis and Messina